Truist Securities Reiterates Buy Rating on Viridian Therapeutics, Inc. (VRDN)

Market Context

Viridian Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $18.82 with a market capitalization of $2.6B.

Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Viridian Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Viridian Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 30, 2026	Wedbush	Outperform	N/A
Jun 30, 2026	Truist Securities	Buy	N/A
Jun 30, 2026	Needham	Buy	N/A
Jun 29, 2026	Wells Fargo	Overweight	N/A
Jun 29, 2026	Needham	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View VRDN Stock Page